{Reference Type}: Journal Article
{Title}: Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
{Author}: Tarantini F;Cumbo C;Anelli L;Zagaria A;Coccaro N;Tota G;Minervini A;Minervini CF;Parciante E;Conserva MR;Redavid I;Specchia G;Musto P;Albano F;
{Journal}: Leuk Lymphoma
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 23
暂无{DOI}: 10.1080/10428194.2024.2381649
{Abstract}: Despite the approval of new drugs, the inclusion of -omics-derived data and the integration of machine learning in both the diagnostic and therapeutic process, the prognosis of acute myeloid leukemia (AML) remains dismal. The curative path is still aimed at achieving a successful allogeneic hematopoietic stem cell transplant (HSCT) in most patients. Nevertheless, access to this procedure is limited to eligible patients. Moreover, post-HSCT outcomes are influenced by AML heterogeneity and patient-related factors. The rise of venetoclax (VEN)-based combinations as standard of care in the treatment of older or unfit AML patients, together with their peculiar management profile, has led researchers to evaluate the feasibility of this approach in patients proceeding toward HSCT. We reviewed the available evidence to weigh up the advantages and pitfalls of this new therapeutic strategy.